Conditions: Ewing Sarcoma; Rhabdomyosarcoma; Synovial Sarcoma
Interventions: Biological: Peptide vaccine IPX
Sponsors: University Hospital Tuebingen; Deutsches Konsortium fürTranslationale Krebsforschung (DKTK); Cooperative Ewing Sarkom Studiengruppe; Cooperative Weichteilsarkom Study Group
Recruiting
Feeds
40322 items (40322 unread) in 74 feeds
Acinar Cell Carcinoma
(947 unread)
Acinic Cell Carcinoma
(353 unread)
Adenoid Cystic Carcinoma
(509 unread)
Adrenal Gland Cancer
(3507 unread)
Ampulla Of Vater
(575 unread)
Anal Cancer
(3208 unread)
Angiosarcoma
(1004 unread)
Appendix Cancer
(1264 unread)
Bile Duct Cancer
(5441 unread)
Brain and CNS
(7735 unread)
Carcinoid
(859 unread)
Endocrine/Neuroendocrine
(6661 unread)
Gall Bladder Cancer
(1824 unread)
Hemangioendothelioma
(1750 unread)
Hepatoblastoma
(545 unread)
Pancreas
(607 unread)
Phyllodes
(491 unread)
PMP and Mucinous Tumors
(396 unread)
Rhabdomyosarcoma
(1282 unread)
Sarcoma
(1364 unread)
Trial - Rhabdomyosarcoma (66 unread)
-
Personalized Vaccination in Fusion+ Sarcoma Patients (PerVision)
Posted: October 23rd, 2023, 2:00am GMT
-
PARP Inhibition, Stereotactic Body Radiotherapy and Immunotherapy for Metastatic or Advanced Sarcoma (PRIMA): a Prospective Phase 2 Trial
Posted: October 10th, 2023, 2:00am GMT
Conditions: Sarcoma; Sarcoma,Soft Tissue; Sarcoma of Bone
Interventions: Combination Product: Camrelizumab and fluzoparib with concurrent stereotactic body radiotherapy (SBRT)
Sponsors: Ruijin Hospital
Recruiting -
Retrospective Study in FFPE Samples From Younger Patients With Rhabdomyosarcoma
Posted: September 15th, 2023, 2:00am GMT
Conditions: Alveolar Childhood Rhabdomyosarcoma; Embryonal Childhood Rhabdomyosarcoma; Recurrent Childhood Rhabdomyosarcoma
Sponsors: Shandong First Medical University; Shandong Tumor Hospital
Completed -
Analyzing Engagement Trends in Rhabdomyosarcoma Clinical Trials
Posted: September 8th, 2023, 2:00pm GMT
Conditions: Rhabdomyosarcoma
Sponsors: Power Life Sciences Inc.
Not yet recruiting -
Treatment of Newly Diagnosed Rhabdomyosarcoma Using Molecular Risk Stratification and Liposomal Irinotecan Based Therapy in Children With Intermediate and High Risk Disease
Posted: September 4th, 2023, 2:00pm GMT
Conditions: Rhabdomyosarcoma
Interventions: Drug: Vincristine; Drug: Dactinomycin; Drug: Cyclophosphamide; Procedure: Surgical Resection; Procedure: Proton beam radiation or external beam radiation or brachytherapy; Drug: Liposomal irinotecan; Drug: Vinorelbine; Drug: Temozolomide; Drug: Filgrastim, peg-filgrastim
Sponsors: St. Jude Children's Research Hospital
Not yet recruiting -
A Phase Ib Trial of Eribulin in Combination With Irinotecan and Temozolamide in Children With Relapsed or Refractory Solid Tumors
Posted: August 23rd, 2023, 2:00pm GMT
Condition: Refractory Solid Tumors
Interventions: Drug: Eribulin; Drug: Irinotecan; Drug: Temozolomide
Sponsor: M.D. Anderson Cancer Center
Recruiting -
Ex Vivo Drug Sensitivity Testing and Multi-Omics Profiling
Posted: May 15th, 2023, 2:00pm GMT
Conditions: Recurrent Childhood Acute Myeloid Leukemia; Recurrent Childhood Acute Lymphoblastic Leukemia; Recurrent Childhood Large Cell Lymphoma; Refractory Childhood Acute Lymphoblastic Leukemia; Refractory Childhood Hodgkin Lymphoma; Refractory Childhood Malignant Germ Cell Neoplasm; Recurrent Childhood Brain Tumor; Recurrent Childhood Brainstem Glioma; Recurrent Childhood Rhabdomyosarcoma; Recurrent Childhood Soft Tissue Sarcoma; Recurrent Childhood Ependymoma; Recurrent Childhood Lymphoblastic Lymphoma; Recurrent Childhood Gliosarcoma; Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Refractory Childhood Malignant Solid Neoplasm; Recurrent Childhood Malignant Solid Neoplasm; Recurrent Childhood Malignant Neoplasm; Refractory Childhood Malignant Neoplasm
Sponsors: Florida International University; Nicklaus Children's Hospital f/k/a Miami Children's Hospital; First Ascent Biomedical, Inc.; National Institute on Minority Health and Health Disparities (NIMHD)
Recruiting -
PRospective rEgistry OF Advanced Stage cancER (PREFER) Patients to Assess Prevalence of Actionable Biomarkers and Driver Mutations to Address Disparities in Precision Medicine
Posted: January 25th, 2023, 3:00pm GMT
Conditions: Lung Cancer; Ovarian Cancer; Uterine Cancer; Colorectal Cancer; Stomach Cancer; Esophageal Cancer; Pancreatic Cancer; Melanoma; Breast Cancer; Head and Neck Cancer; Soft Tissue Sarcoma; Rhabdomyosarcoma; Prostate Cancer
Intervention: Diagnostic Test: OmniSeq Test
Sponsor: Labcorp Corporation of America Holdings, Inc
Recruiting -
A Multi-Institution Study of TGFβ Imprinted, Ex Vivo Expanded Universal Donor NK Cell Infusions as Adoptive Immunotherapy in Combination With Gemcitabine and Docetaxel in Patients With Relapsed or Refractory Pediatric Bone and Soft Tissue
Posted: December 2nd, 2022, 3:00pm GMT
Conditions: Pediatric Sarcoma, Refractory; Pediatric Sarcoma, Relapsed
Interventions: Biological: GEM/DOX + TGFBi expanded NK cells
Sponsors: Nationwide Children's Hospital; National Pediatric Cancer Foundation
Recruiting -
Doxorubicin Hydrochloride Liposome Combined With Irinotecan Versus VIT Regimen in the Treatment of Pediatric Rhabdomyosarcoma
Posted: July 14th, 2022, 2:00pm GMT
Conditions: Rhabdomyosarcoma, Child
Interventions: Drug: Doxorubicin Hydrochloride Liposome+Irinotecan; Drug: Temozolomide+Irinotecan+Vincristine
Sponsors: Sun Yat-sen University; CSPC Ouyi Pharmaceutical Co., Ltd.
Not yet recruiting -
Study of Efficacy and Safety of Ribociclib (LEE011) in Combination With Topotecan and Temozolomide (TOTEM) in Pediatric Patients With Relapsed or Refractory Neuroblastoma and Other Solid Tumors
Posted: June 23rd, 2022, 2:00pm GMT
Conditions: Neuroblastoma
Interventions: Drug: Topotecan; Drug: Temozolomide; Drug: Ribociclib
Sponsors: Novartis Pharmaceuticals; Innovative Therapies For Children with Cancer Consortium
Recruiting -
Chemotherapy for the Treatment of Patients With Newly Diagnosed Very Low-Risk and Low Risk Fusion Negative Rhabdomyosarcoma
Posted: March 31st, 2022, 2:00pm GMT
Conditions: Embryonal Rhabdomyosarcoma; Fusion-Negative Alveolar Rhabdomyosarcoma; Spindle Cell/Sclerosing Rhabdomyosarcoma
Interventions: Procedure: Biopsy; Procedure: Bone Scan; Procedure: Computed Tomography; Drug: Cyclophosphamide; Biological: Dactinomycin; Procedure: Magnetic Resonance Elastography; Procedure: Positron Emission Tomography; Radiation: Radiation Therapy; Drug: Vincristine
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting -
Neoadjuvant Dual Checkpoint Inhibition and Cryoablation in Relapsed/Refractory Pediatric Solid Tumors
Posted: March 31st, 2022, 2:00am GMT
Conditions: Osteosarcoma; Ewing Sarcoma; Rhabdomyosarcoma; Relapsed Pediatric Solid Tumor; Refractory Pediatric Solid Tumor; Melanoma; Hepatoblastoma; Hepatocellular Carcinoma; Neuroblastoma; Wilms Tumor
Interventions: Procedure: Cryoablation Therapy; Drug: Nivolumab; Drug: Ipilimumab
Sponsors: Children's National Research Institute; Bristol-Myers Squibb
Active, not recruiting -
A Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations
Posted: January 20th, 2022, 3:00pm GMT
Condition: Solid Tumors With PTCH1 Loss-of-function Mutations
Intervention: Drug: ENV-101 (taladegib)
Sponsor: Endeavor Biomedicines, Inc.
Recruiting -
A Study of Cabozantinib as a Maintenance Agent to Prevent Progression or Recurrence in High-Risk Pediatric Solid Tumors
Posted: November 26th, 2021, 3:00pm GMT
Conditions: Neuroblastoma; Sarcoma
Intervention: Drug: Cabozantinib
Sponsors: Nationwide Children's Hospital; Exelixis
Recruiting -
Multicohort Trial of Trabectedin and Low-dose Radiation Therapy in Advanced/Metastatic Sarcomas
Posted: November 23rd, 2021, 3:00pm GMT
Conditions: Soft Tissue Sarcoma; Bone Tumors; Small Round-cell Sarcomas
Intervention: Drug: Trabectedin
Sponsor: Grupo Espanol de Investigacion en Sarcomas
Recruiting -
Improving Adolescent and Young Adult Self-Reported Data in ECOG-ACRIN Trials
Posted: November 4th, 2021, 2:00am GMT
Conditions: Breast Cancer, NOS; CNS Primary Tumor, NOS; Cervical Cancer, NOS; Colorectal Cancer, NOS; Leukemia, NOS; Lymphoma, NOS; Miscellaneous Neoplasm, NOS; Non-Rhabdomyosarcoma Soft Tissue Sarcoma, NOS; Testicular Nonseminomatous Germ Cell Tumor, NOS; Thyroid Cancer, NOS; Melanoma; Bone Cancer, NOS
Interventions: Other: Questionnaires
Sponsors: Eastern Cooperative Oncology Group
Recruiting -
Interleukin-15 Armored Glypican 3-specific Chimeric Antigen Receptor Expressed in Autologous T Cells for Hepatocellular Carcinoma
Posted: November 2nd, 2021, 2:00pm GMT
Conditions: Liver Cell Carcinoma; Solid Tumor; Wilms Tumor; Malignant Rhabdoid Tumor; Yolk Sac Tumor; Rhabdomyosarcoma; Liposarcoma; Embryonal Sarcoma of the Liver
Intervention: Genetic: CATCH T cells
Sponsors: Baylor College of Medicine; Center for Cell and Gene Therapy, Baylor College of Medicine; The Methodist Hospital Research Institute
Recruiting -
Comparison Capsule Sparing Cystectomy and Radical Cystoprostatectomy in Men With Bladder Cancer
Posted: October 5th, 2021, 2:00am GMT
Conditions: Bladder Cancer
Interventions: Procedure: Capsule Sparing Cystectomy (CSC); Procedure: Conventional Radical Cystoprostatectomy (CRC)
Sponsors: Zhujiang Hospital
Not yet recruiting -
Comparing Carbon Ion Therapy, Surgery, and Proton Therapy for Management of Pelvic Sarcomas Involving the Bone
Posted: September 2nd, 2021, 2:00pm GMT
Conditions: Bone Sarcoma; Chondrosarcoma; Chordoma; Ewing Sarcoma of Bone; Pelvic Rhabdomyosarcoma
Interventions: Other: Electronic Health Record Review; Other: Quality-of-Life Assessment
Sponsors: Mayo Clinic
Recruiting -
HER2 Chimeric Antigen Receptor (CAR) T Cells in Combination With Checkpoint Blockade in Patients With Advanced Sarcoma
Posted: August 6th, 2021, 2:00pm GMT
Conditions: Sarcoma; HER-2 Protein Overexpression; Osteosarcoma; Rhabdomyosarcoma; Ewing Sarcoma; Synovial Sarcoma; Soft Tissue Sarcoma; Undifferentiated Sarcoma
Interventions: Genetic: T cells or CAR T cells; Drug: Pembrolizumab Injectable Product; Drug: Nivolumab Injectable Product
Sponsors: Baylor College of Medicine; Center for Cell and Gene Therapy, Baylor College of Medicine; The Faris Foundation USA; Stand Up To Cancer; Triumph Over Kid Cancer Foundation; St. Baldrick's Foundation; National Cancer Institute (NCI)
Recruiting -
B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)
Posted: May 21st, 2021, 2:00pm GMT
Conditions: Pediatric Solid Tumor; Osteosarcoma; Rhabdomyosarcoma; Neuroblastoma; Ewing Sarcoma; Wilms Tumor; Adrenocortical Cancer; Desmoplastic Small Round Cell Tumor; Germ Cell Cancer; Rhabdoid Tumor; Clear Cell Sarcoma; Hepatoblastoma; Melanoma; Carcinoma; Malignant Peripheral Nerve Sheath Tumors; Soft Tissue Sarcoma
Interventions: Drug: Fludarabine; Drug: Cyclophosphamide; Drug: MESNA; Drug: B7-H3 CAR T cells
Sponsor: St. Jude Children's Research Hospital
Recruiting -
A Pilot Study of Thermodox and MR-HIFU for Treatment of Relapsed Solid Tumors
Posted: March 10th, 2021, 3:00pm GMT
Conditions: Solid Tumors; Soft Tissue Sarcoma; Ewing Sarcoma; Malignant Epithelial Neoplasm; Rhabdomyosarcoma; Wilms Tumor; Hepatic Tumor; Germ Cell Tumor; Bone Metastases
Interventions: Device: Magnetic Resonance-Guided High Intensity Focused Ultrasound; Drug: Lyso-thermosensitive Liposomal Doxorubicin
Sponsor: Children's National Research Institute
Recruiting -
Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors
Posted: January 20th, 2021, 3:00pm GMT
Conditions: Liver Cancer; Rhabdomyosarcoma; Malignant Rhabdoid Tumor; Liposarcoma; Wilms Tumor; Yolk Sac Tumor
Interventions: Genetic: CARE T cells; Drug: Cytoxan; Drug: Fludara
Sponsors: Baylor College of Medicine; Center for Cell and Gene Therapy, Baylor College of Medicine
Not yet recruiting -
FaR-RMS: An Overarching Study for Children and Adults With Frontline and Relapsed RhabdoMyoSarcoma
Posted: November 12th, 2020, 3:00pm GMT
Condition: Rhabdomyosarcoma
Interventions: Drug: Irinotecan; Drug: Actinomycin D; Drug: Doxorubicin; Drug: Ifosfamide; Drug: Vincristine; Drug: Vinorelbine; Drug: Cyclophosphamide; Drug: Temozolomide; Radiation: radiotherapy; Drug: Regorafenib
Sponsor: University of Birmingham
Recruiting -
A Study of Lenvatinib (MK-7902) in Pediatric Participants With Relapsed or Refractory Solid Malignancies (MK-7902-013/E7080)
Posted: June 25th, 2020, 2:00am GMT
Conditions: Relapsed or Refractory Solid Tumors
Interventions: Drug: Lenvatinib
Sponsors: Merck Sharp & Dohme LLC; Eisai Inc.
Active, not recruiting -
Personalized Risk-Adapted Therapy in Post-Pubertal Patients With Newly-Diagnosed Medulloblastoma
Posted: May 26th, 2020, 2:00pm GMT
Condition: Medulloblastoma
Interventions: Drug: Sonidegib; Drug: Cisplatin; Drug: Lomustine; Drug: Vincristine; Radiation: radiotherapy
Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
Recruiting -
Evolutionary Therapy for Rhabdomyosarcoma
Posted: May 14th, 2020, 2:00pm GMT
Conditions: Rhabdomyosarcoma
Interventions: Drug: Vincristine; Drug: Cyclophosphamide; Drug: Vinorelbine; Drug: Actinomycin D; Drug: Cyclophosphamide Pill
Sponsors: H. Lee Moffitt Cancer Center and Research Institute; National Pediatric Cancer Foundation
Recruiting -
Flavored, Oral Irinotecan VAL-413 (Orotecan®) Given With Temozolomide for Treatment of Recurrent Pediatric Solid Tumors
Posted: April 7th, 2020, 2:00pm GMT
Conditions: Solid Tumors; Neuroblastoma; Rhabdomyosarcoma; Ewing Sarcoma; Hepatoblastoma; Medulloblastoma
Interventions: Drug: VAL-413; Drug: Temozolomide
Sponsor: Valent Technologies, LLC
Recruiting -
Vorinostat in Combination With Chemotherapy in Relapsed/Refractory Solid Tumors and CNS Malignancies
Posted: March 16th, 2020, 2:00am GMT
Conditions: Ewing Sarcoma; Rhabdomyosarcoma; Wilms Tumor; Neuroblastoma; Hepatoblastoma; Germ Cell Tumor
Interventions: Drug: Vorinostat
Sponsors: New York Medical College
Recruiting -
Mocetinostat With Vinorelbine in Children, Adolescents & Young Adults With Refractory and/or Recurrent Rhabdomyosarcoma
Posted: March 6th, 2020, 3:00pm GMT
Condition: Rhabdomyosarcoma
Interventions: Drug: Vinorelbine; Drug: Mocetinostat
Sponsors: Jonsson Comprehensive Cancer Center; Mirati Therapeutics Inc.; Phase One Foundation
Recruiting -
Heated Intra-peritoneal Chemotherapy With Doxorubicin and Cisplatin for the Treatment of Resectable, Refractory, or Recurrent Abdominal or Pelvic Tumors in Pediatric Patients, T.O.A.S.T. I.T. Study
Posted: December 30th, 2019, 3:00pm GMT
Conditions: Malignant Abdominal Neoplasm; Malignant Pelvic Neoplasm; Recurrent Colon Carcinoma; Recurrent Desmoplastic Small Round Cell Tumor; Recurrent Fallopian Tube Carcinoma; Recurrent Gastric Carcinoma; Recurrent Liposarcoma; Recurrent Malignant Mesothelioma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma; Recurrent Rectal Carcinoma; Recurrent Rhabdomyosarcoma; Recurrent Sarcoma; Refractory Colon Carcinoma; Refractory Desmoplastic Small Round Cell Tumor; Refractory Fallopian Tube Carcinoma; Refractory Gastric Carcinoma; Refractory Liposarcoma; Refractory Malignant Mesothelioma; Refractory Ovarian Carcinoma; Refractory Primary Peritoneal Carcinoma; Refractory Rectal Carcinoma; Refractory Rhabdomyosarcoma; Refractory Sarcoma; Resectable Liposarcoma; Resectable Malignant Mesothelioma; Resectable Sarcoma
Interventions: Drug: Cisplatin; Procedure: Cytoreductive Surgery; Drug: Doxorubicin; Drug: Hyperthermic Intraperitoneal Chemotherapy; Drug: Sodium Thiosulfate
Sponsors: Mayo Clinic; National Cancer Institute (NCI)
Recruiting -
A Study of the Drugs Prexasertib, Irinotecan, and Temozolomide in People With Desmoplastic Small Round Cell Tumor and Rhabdomyosarcoma
Posted: September 19th, 2019, 2:00am GMT
Conditions: Desmoplastic Small Round Cell Tumor; Rhabdomyosarcoma
Interventions: Drug: Prexasertib; Drug: Irinotecan
Sponsors: Memorial Sloan Kettering Cancer Center
Active, not recruiting -
Indocyanine Green (ICG) Guided Tumor Resection
Posted: September 10th, 2019, 2:00pm GMT
Conditions: Neoplastic Disease; Solid Tumor
Interventions: Drug: Indocyanine Green
Sponsors: St. Jude Children's Research Hospital
Recruiting -
Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid Tumors
Posted: October 17th, 2018, 2:00pm GMT
Conditions: Ewing Sarcoma; Solid Tumors; Rhabdoid Tumor; Rhabdomyosarcoma; Neuroblastoma; Medulloblastoma; Diffuse Intrinsic Pontine Glioma
Interventions: Drug: Palbociclib; Drug: Temozolomide; Drug: Irinotecan; Drug: Topotecan; Drug: Cyclophosphamide
Sponsors: Pfizer; Children's Oncology Group (COG)
Recruiting -
Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)
Posted: October 9th, 2018, 2:00am GMT
Conditions: Advanced Malignant Solid Neoplasm; Recurrent Ependymal Tumor; Recurrent Ewing Sarcoma; Recurrent Glioma; Recurrent Hepatoblastoma; Recurrent Histiocytic and Dendritic Cell Neoplasm; Recurrent Langerhans Cell Histiocytosis; Recurrent Malignant Germ Cell Tumor; Recurrent Malignant Solid Neoplasm; Recurrent Medulloblastoma; Recurrent Neuroblastoma; Recurrent Non-Hodgkin Lymphoma; Recurrent Osteosarcoma; Recurrent Peripheral Primitive Neuroectodermal Tumor; Recurrent Primary Malignant Central Nervous System Neoplasm; Recurrent Rhabdoid Tumor; Recurrent Rhabdomyosarcoma; Recurrent Soft Tissue Sarcoma; Refractory Ependymoma; Refractory Ewing Sarcoma; Refractory Glioma; Refractory Hepatoblastoma; Refractory Histiocytic and Dendritic Cell Neoplasm; Refractory Langerhans Cell Histiocytosis; Refractory Malignant Germ Cell Tumor; Refractory Malignant Solid Neoplasm; Refractory Medulloblastoma; Refractory Neuroblastoma; Refractory Non-Hodgkin Lymphoma; Refractory Osteosarcoma; Refractory Peripheral Primitive Neuroectodermal Tumor; Refractory Primary Malignant Central Nervous System Neoplasm; Refractory Rhabdoid Tumor; Refractory Rhabdomyosarcoma; Refractory Soft Tissue Sarcoma; Wilms Tumor
Interventions: Other: Pharmacokinetic Study; Drug: Ulixertinib
Sponsors: National Cancer Institute (NCI)
Active, not recruiting -
C7R-GD2.CART Cells for Patients With Relapsed or Refractory Neuroblastoma and Other GD2 Positive Cancers (GAIL-N)
Posted: August 17th, 2018, 2:00pm GMT
Conditions: Relapsed Neuroblastoma; Refractory Neuroblastoma; Relapsed Osteosarcoma; Relapsed Ewing Sarcoma; Relapsed Rhabdomyosarcoma; Uveal Melanoma; Phyllodes Breast Tumor
Intervention: Genetic: C7R-GD2.CART cells
Sponsors: Baylor College of Medicine; Center for Cell and Gene Therapy, Baylor College of Medicine; The Methodist Hospital Research Institute; Cancer Prevention Research Institute of Texas
Recruiting -
EGFR806 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults
Posted: August 7th, 2018, 2:00pm GMT
Conditions: Pediatric Solid Tumor; Germ Cell Tumor; Retinoblastoma; Hepatoblastoma; Wilms Tumor; Rhabdoid Tumor; Carcinoma; Osteosarcoma; Ewing Sarcoma; Rhabdomyosarcoma; Synovial Sarcoma; Clear Cell Sarcoma; Malignant Peripheral Nerve Sheath Tumors; Desmoplastic Small Round Cell Tumor; Soft Tissue Sarcoma; Neuroblastoma
Interventions: Biological: second generation 4-1BBζ EGFR806-EGFRt; Biological: second generation 4-1BBζ EGFR806-EGFRt and a second generation 4 1BBζ CD19-Her2tG
Sponsor: Seattle Children's Hospital
Recruiting -
Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial)
Posted: May 16th, 2018, 2:00am GMT
Conditions: Advanced Malignant Solid Neoplasm; Recurrent Childhood Ependymoma; Recurrent Ewing Sarcoma; Recurrent Glioma; Recurrent Hepatoblastoma; Recurrent Kidney Wilms Tumor; Recurrent Langerhans Cell Histiocytosis; Recurrent Malignant Germ Cell Tumor; Recurrent Malignant Glioma; Recurrent Medulloblastoma; Recurrent Neuroblastoma; Recurrent Non-Hodgkin Lymphoma; Recurrent Osteosarcoma; Recurrent Peripheral Primitive Neuroectodermal Tumor; Recurrent Rhabdoid Tumor; Recurrent Rhabdomyosarcoma; Recurrent Soft Tissue Sarcoma; Refractory Ependymoma; Refractory Ewing Sarcoma; Refractory Glioma; Refractory Hepatoblastoma; Refractory Langerhans Cell Histiocytosis; Refractory Malignant Germ Cell Tumor; Refractory Malignant Glioma; Refractory Medulloblastoma; Refractory Neuroblastoma; Refractory Non-Hodgkin Lymphoma; Refractory Osteosarcoma; Refractory Peripheral Primitive Neuroectodermal Tumor; Refractory Rhabdoid Tumor; Refractory Rhabdomyosarcoma; Refractory Soft Tissue Sarcoma
Interventions: Other: Laboratory Biomarker Analysis; Drug: Palbociclib; Other: Pharmacological Study
Sponsors: National Cancer Institute (NCI)
Active, not recruiting -
Biological Characterisation of High Risk CHildhood Cancer in Children, Adolescents and Young Adults (MICCHADO)
Posted: April 12th, 2018, 2:00pm GMT
Conditions: Neuroblastoma; Rhabdomyosarcoma; Ewing Sarcoma Family of Tumors; Osteosarcoma; Leukemia; Central Nervous System Tumor
Interventions: Other: Sampling on blood, bone marrow and cerebrospinal fluid
Sponsors: Institut Curie
Recruiting -
Safety, Tolerability, Efficacy and Pharmacokinetics of Copanlisib in Pediatric Patients
Posted: March 8th, 2018, 3:00am GMT
Conditions: Relapsed or Refractory Solid Tumors or Lymphoma in Children; Neuroblastoma; Osteosarcoma; Rhabdomyosarcoma; Ewing Sarcoma
Interventions: Drug: Copanlisib (BAY806946)
Sponsors: Bayer
Terminated -
Study of Lenvatinib in Combination With Everolimus in Recurrent and Refractory Pediatric Solid Tumors, Including Central Nervous System Tumors
Posted: August 10th, 2017, 2:00am GMT
Conditions: Recurrent and Refractory Solid Tumors
Interventions: Drug: Lenvatinib; Drug: Everolimus
Sponsors: Eisai Inc.; Merck Sharp & Dohme LLC
Completed -
Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial)
Posted: July 28th, 2017, 2:00am GMT
Conditions: Advanced Malignant Solid Neoplasm; Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma; Ann Arbor Stage IV Childhood Non-Hodgkin Lymphoma; Low Grade Glioma; Malignant Glioma; Recurrent Childhood Central Nervous System Neoplasm; Recurrent Childhood Ependymoma; Recurrent Childhood Malignant Germ Cell Tumor; Recurrent Childhood Non-Hodgkin Lymphoma; Recurrent Childhood Rhabdomyosarcoma; Recurrent Childhood Soft Tissue Sarcoma; Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor; Recurrent Glioma; Recurrent Hepatoblastoma; Recurrent Langerhans Cell Histiocytosis; Recurrent Malignant Solid Neoplasm; Recurrent Medulloblastoma; Recurrent Neuroblastoma; Recurrent Osteosarcoma; Refractory Childhood Malignant Germ Cell Tumor; Refractory Ependymoma; Refractory Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor; Refractory Glioma; Refractory Hepatoblastoma; Refractory Langerhans Cell Histiocytosis; Refractory Malignant Glioma; Refractory Malignant Solid Neoplasm; Refractory Medulloblastoma; Refractory Neuroblastoma; Refractory Non-Hodgkin Lymphoma; Refractory Osteosarcoma; Refractory Primary Central Nervous System Neoplasm; Refractory Rhabdomyosarcoma; Refractory Soft Tissue Sarcoma; Rhabdoid Tumor; Wilms Tumor
Interventions: Drug: Olaparib
Sponsors: National Cancer Institute (NCI)
Active, not recruiting -
Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial)
Posted: July 18th, 2017, 2:00am GMT
Conditions: Advanced Malignant Solid Neoplasm; Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma; Ann Arbor Stage IV Childhood Non-Hodgkin Lymphoma; Ependymoma; Ewing Sarcoma; Hepatoblastoma; Langerhans Cell Histiocytosis; Malignant Germ Cell Tumor; Malignant Glioma; Osteosarcoma; Peripheral Primitive Neuroectodermal Tumor; Recurrent Childhood Central Nervous System Neoplasm; Recurrent Childhood Non-Hodgkin Lymphoma; Recurrent Malignant Solid Neoplasm; Recurrent Neuroblastoma; Refractory Malignant Solid Neoplasm; Refractory Neuroblastoma; Refractory Non-Hodgkin Lymphoma; Refractory Primary Central Nervous System Neoplasm; Rhabdoid Tumor; Rhabdomyosarcoma; Soft Tissue Sarcoma; Wilms Tumor
Interventions: Other: Laboratory Biomarker Analysis; Drug: Vemurafenib
Sponsors: National Cancer Institute (NCI)
Active, not recruiting -
Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial)
Posted: July 11th, 2017, 2:00am GMT
Conditions: Advanced Malignant Solid Neoplasm; Ann Arbor Stage III Hodgkin Lymphoma; Ann Arbor Stage III Non-Hodgkin Lymphoma; Ann Arbor Stage IV Hodgkin Lymphoma; Ann Arbor Stage IV Non-Hodgkin Lymphoma; Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor; Low Grade Glioma; Recurrent Ependymoma; Recurrent Ewing Sarcoma; Recurrent Glioma; Recurrent Hepatoblastoma; Recurrent Hodgkin Lymphoma; Recurrent Langerhans Cell Histiocytosis; Recurrent Malignant Germ Cell Tumor; Recurrent Malignant Glioma; Recurrent Malignant Solid Neoplasm; Recurrent Medulloblastoma; Recurrent Neuroblastoma; Recurrent Non-Hodgkin Lymphoma; Recurrent Osteosarcoma; Recurrent Peripheral Primitive Neuroectodermal Tumor; Recurrent Primary Central Nervous System Neoplasm; Recurrent Rhabdoid Tumor; Recurrent Rhabdomyosarcoma; Recurrent Soft Tissue Sarcoma; Refractory Hodgkin Lymphoma; Refractory Langerhans Cell Histiocytosis; Refractory Malignant Germ Cell Tumor; Refractory Malignant Glioma; Refractory Malignant Solid Neoplasm; Refractory Medulloblastoma; Refractory Neuroblastoma; Refractory Non-Hodgkin Lymphoma; Refractory Osteosarcoma; Refractory Peripheral Primitive Neuroectodermal Tumor; Refractory Rhabdoid Tumor; Refractory Soft Tissue Sarcoma; Rhabdoid Tumor; Stage III Soft Tissue Sarcoma AJCC v7; Stage IV Soft Tissue Sarcoma AJCC v7; Wilms Tumor
Interventions: Drug: Tazemetostat
Sponsors: National Cancer Institute (NCI); Children's Oncology Group
Active, not recruiting -
Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)
Posted: July 7th, 2017, 2:00am GMT
Conditions: Advanced Malignant Solid Neoplasm; Recurrent Childhood Ependymoma; Recurrent Childhood Malignant Germ Cell Tumor; Recurrent Childhood Medulloblastoma; Recurrent Childhood Non-Hodgkin Lymphoma; Recurrent Childhood Osteosarcoma; Recurrent Childhood Rhabdomyosarcoma; Recurrent Childhood Soft Tissue Sarcoma; Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor; Recurrent Hepatoblastoma; Recurrent Langerhans Cell Histiocytosis; Recurrent Malignant Glioma; Recurrent Malignant Solid Neoplasm; Recurrent Neuroblastoma; Recurrent Primary Central Nervous System Neoplasm; Recurrent Rhabdoid Tumor; Refractory Childhood Malignant Germ Cell Tumor; Refractory Childhood Osteosarcoma; Refractory Childhood Rhabdomyosarcoma; Refractory Childhood Soft Tissue Sarcoma; Refractory Ependymoma; Refractory Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor; Refractory Hepatoblastoma; Refractory Langerhans Cell Histiocytosis; Refractory Malignant Glioma; Refractory Malignant Solid Neoplasm; Refractory Medulloblastoma; Refractory Neuroblastoma; Refractory Non-Hodgkin Lymphoma; Refractory Primary Central Nervous System Neoplasm; Refractory Rhabdoid Tumor; Wilms Tumor
Interventions: Procedure: Biospecimen Collection; Procedure: Bone Marrow Aspiration and Biopsy; Procedure: Bone Scan; Procedure: Computed Tomography; Drug: Erdafitinib; Other: Laboratory Biomarker Analysis; Procedure: Magnetic Resonance Imaging; Other: Pharmacological Study; Procedure: Positron Emission Tomography; Procedure: Radionuclide Imaging; Procedure: X-Ray Imaging
Sponsors: National Cancer Institute (NCI)
Active, not recruiting -
Comparison of Safety and Efficacy of Detaenial Sigmoid Neobladder and Ileal Neobladder
Posted: April 11th, 2017, 2:00am GMT
Conditions: Bladder Cancer; Urinary Diversion
Interventions: Procedure: sigmoid; Procedure: ileal
Sponsors: Zhujiang Hospital; Sun Yat-sen University; The Third Affiliated Hospital of Southern Medical University; Fourth Affiliated Hospital of Guangxi Medical University; Ludwig-Maximilians - University of Munich
Recruiting -
Familial Investigations of Childhood Cancer Predisposition
Posted: February 10th, 2017, 3:00pm GMT
Conditions: Acute Leukemia; Adenomatous Polyposis; Adrenocortical Carcinoma; AML; BAP1 Tumor Predisposition Syndrome; Carney Complex; Choroid Plexus Carcinoma; Constitutional Mismatch Repair Deficiency Syndrome; Diamond-Blackfan Anemia; DICER1 Syndrome; Dyskeratosis Congenita; Emberger Syndrome; Familial Acute Myeloid Leukemia; Familial Adenomatous Polyposis; Fanconi Anemia; Familial Cancer; Familial Wilms Tumor; Familial Neuroblastoma; GIST; Hereditary Breast and Ovarian Cancer; Hereditary Paraganglioma-Pheochromocytoma Syndrome; Hodgkin Lymphoma; Juvenile Polyposis; Li-Fraumeni Syndrome; Lynch Syndrome; MDS; Melanoma Syndrome; Multiple Endocrine Neoplasia Type 1; Multiple Endocrine Neoplasia Type 2; Neuroblastoma; Neurofibromatosis Type 1; Neurofibromatosis Type II; Nevoid Basal Cell Carcinoma Syndrome; Non Hodgkin Lymphoma; Noonan Syndrome and Other Rasopathy; Overgrowth Syndromes; Pancreatic Cancer; Peutz-Jeghers Syndrome; Pheochromocytoma/Paraganglioma; PTEN Hamartoma Tumor Syndrome; Retinoblastoma; Rhabdoid Tumor Predisposition Syndrome; Rhabdomyosarcoma; Rothmund-Thomson Syndrome; Tuberous Sclerosis; Von Hippel-Lindau Disease
Intervention:
Sponsor: St. Jude Children's Research Hospital
Recruiting -
Nab-Paclitaxel and Gemcitabine for Recurrent/Refractory Sarcoma
Posted: October 26th, 2016, 2:00pm GMT
Conditions: Osteosarcoma; Ewing Sarcoma; Rhabdomyosarcoma; Soft Tissue Sarcoma
Interventions: Drug: nab-Paclitaxel; Drug: Gemcitabine
Sponsors: H. Lee Moffitt Cancer Center and Research Institute; National Pediatric Cancer Foundation
Recruiting -
Abemaciclib in Children With DIPG or Recurrent/Refractory Solid Tumors
Posted: December 31st, 2015, 3:00am GMT
Conditions: Diffuse Intrinsic Pontine Glioma; Brain Tumor, Recurrent; Solid Tumor, Recurrent; Neuroblastoma, Recurrent, Refractory; Ewing Sarcoma, Recurrent, Refractory; Rhabdomyosarcoma, Recurrent, Refractory; Osteosarcoma, Recurrent, Refractory; Rhabdoid Tumor, Recurrent, Refractory
Interventions: Drug: Abemaciclib
Sponsors: Emory University
Completed -
Combination Chemotherapy With or Without Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma
Posted: October 5th, 2015, 2:00am GMT
Conditions: Alveolar Rhabdomyosarcoma; Botryoid-Type Embryonal Rhabdomyosarcoma; Embryonal Rhabdomyosarcoma; Rhabdomyosarcoma; Sclerosing Rhabdomyosarcoma; Spindle Cell Rhabdomyosarcoma
Interventions: Drug: Cyclophosphamide; Biological: Dactinomycin; Drug: Irinotecan Hydrochloride; Other: Laboratory Biomarker Analysis; Other: Questionnaire Administration; Radiation: Radiation Therapy; Drug: Temsirolimus; Drug: Vincristine Sulfate; Drug: Vinorelbine
Sponsors: National Cancer Institute (NCI)
Active, not recruiting -
Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas
Posted: December 2nd, 2014, 3:00am GMT
Conditions: Metastatic Melanoma; Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor; Recurrent Hodgkin Lymphoma; Recurrent Malignant Solid Neoplasm; Recurrent Melanoma; Recurrent Neuroblastoma; Recurrent Non-Hodgkin Lymphoma; Recurrent Osteosarcoma; Recurrent Rhabdomyosarcoma; Refractory Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor; Refractory Hodgkin Lymphoma; Refractory Malignant Solid Neoplasm; Refractory Melanoma; Refractory Neuroblastoma; Refractory Non-Hodgkin Lymphoma; Refractory Osteosarcoma; Refractory Rhabdomyosarcoma; Stage III Cutaneous Melanoma AJCC v7; Stage IIIA Cutaneous Melanoma AJCC v7; Stage IIIB Cutaneous Melanoma AJCC v7; Stage IIIC Cutaneous Melanoma AJCC v7; Stage IV Cutaneous Melanoma AJCC v6 and v7; Unresectable Melanoma
Interventions: Biological: Ipilimumab; Other: Laboratory Biomarker Analysis; Biological: Nivolumab; Other: Pharmacological Study
Sponsors: National Cancer Institute (NCI)
Completed -
Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery
Posted: July 3rd, 2014, 2:00am GMT
Conditions: Alveolar Soft Part Sarcoma; Angiomatoid Fibrous Histiocytoma; Atypical Fibroxanthoma; Clear Cell Sarcoma of Soft Tissue; Epithelioid Malignant Peripheral Nerve Sheath Tumor; Epithelioid Sarcoma; Extraskeletal Myxoid Chondrosarcoma; Extraskeletal Osteosarcoma; Fibrohistiocytic Neoplasm; Fibrosarcoma; Inflammatory Myofibroblastic Tumor; Intimal Sarcoma; Leiomyosarcoma; Liposarcoma; Liver Embryonal Sarcoma; Low Grade Fibromyxoid Sarcoma; Low Grade Myofibroblastic Sarcoma; Malignant Cutaneous Granular Cell Tumor; Malignant Peripheral Nerve Sheath Tumor; Malignant Triton Tumor; Mesenchymal Chondrosarcoma; Myxofibrosarcoma; Myxoid Chondrosarcoma; Myxoinflammatory Fibroblastic Sarcoma; Nerve Sheath Neoplasm; PEComa; Pericytic Neoplasm; Plexiform Fibrohistiocytic Tumor; Sclerosing Epithelioid Fibrosarcoma; Skin Glomus Tumor; Stage IB Soft Tissue Sarcoma AJCC v7; Stage IIB Soft Tissue Sarcoma AJCC v7; Stage III Soft Tissue Sarcoma AJCC v7; Stage IV Soft Tissue Sarcoma AJCC v7; Synovial Sarcoma; Undifferentiated High Grade Pleomorphic Sarcoma of Bone
Interventions: Drug: Doxorubicin; Drug: Doxorubicin Hydrochloride; Drug: Ifosfamide; Drug: Pazopanib; Drug: Pazopanib Hydrochloride; Radiation: Radiation Therapy; Procedure: Therapeutic Conventional Surgery
Sponsors: National Cancer Institute (NCI)
Active, not recruiting -
Molecular-Guided Therapy for Childhood Cancer
Posted: June 13th, 2014, 2:00am GMT
Conditions: Neuroblastoma; Medulloblastoma; Glioma; Ependymoma; Choroid Plexus Neoplasms; Craniopharyngioma; Dysembryoplastic Neuroepithelial Tumor; Meningioma; Primitive Neuroectodermal Tumors (PNETs); Germ Cell Tumors; Rhabdomyosarcoma; Non-rhabdomyosarcoma; Ewings Sarcoma; Osteosarcoma; Wilms Tumor; Renal Cell Carcinoma; Malignant Rhabdoid Tumor; Clear Cell Sarcoma; Liver Tumors
Interventions: Device: Guided Therapy
Sponsors: Giselle Sholler; Translational Genomics Research Institute; Dell, Inc.
Active, not recruiting -
Adavosertib and Irinotecan Hydrochloride in Treating Younger Patients With Relapsed or Refractory Solid Tumors
Posted: March 24th, 2014, 2:00am GMT
Conditions: Central Nervous System Embryonal Tumor With Rhabdoid Features; Central Nervous System Embryonal Tumor, Not Otherwise Specified; Central Nervous System Ganglioneuroblastoma; Embryonal Tumor With Multilayered Rosettes, C19MC-Altered; Pineoblastoma; Primary Central Nervous System Neoplasm; Recurrent Childhood Central Nervous System Embryonal Neoplasm; Recurrent Malignant Solid Neoplasm; Recurrent Medulloblastoma; Recurrent Neuroblastoma; Recurrent Rhabdomyosarcoma; Refractory Malignant Solid Neoplasm; Refractory Medulloblastoma; Refractory Neuroblastoma; Refractory Rhabdomyosarcoma
Interventions: Drug: Adavosertib; Drug: Irinotecan Hydrochloride
Sponsors: National Cancer Institute (NCI)
Completed -
A Phase I Dose Finding Study in Children With Solid Tumors Recurrent or Refractory to Standard Therapy
Posted: March 12th, 2014, 2:00am GMT
Conditions: Pediatric Oncology
Interventions: Drug: Regorafenib (BAY73-4506); Drug: Vincristine (Cellcristin®); Drug: Irinotecan (Irinotecan Cell pharm®)
Sponsors: Bayer
Active, not recruiting -
SARC024: A Blanket Protocol to Study Oral Regorafenib in Patients With Selected Sarcoma Subtypes
Posted: January 29th, 2014, 3:00am GMT
Conditions: Liposarcoma; Osteogenic Sarcoma; Ewing/Ewing-like Sarcoma; Rhabdomyosarcoma; Mesenchymal Chondrosarcoma
Interventions: Drug: Regorafenib; Drug: Placebo
Sponsors: Sarcoma Alliance for Research through Collaboration
Completed -
Risk-Adapted Focal Proton Beam Radiation and/or Surgery in Patients With Low, Intermediate and High Risk Rhabdomyosarcoma Receiving Standard or Intensified Chemotherapy
Posted: June 7th, 2013, 2:00am GMT
Conditions: Rhabdomyosarcoma
Interventions: Drug: Vincristine; Drug: Dactinomycin; Drug: Cyclophosphamide; Procedure: Surgical Resection; Procedure: Radiation; Drug: Bevacizumab; Drug: Sorafenib; Drug: Myeloid Growth Factor; Procedure: Lymph Node Sampling; Drug: Irinotecan; Drug: Ifosfamide; Drug: Etoposide; Drug: Etoposide Phosphate; Drug: Doxorubicin; Drug: Dexrazoxane; Drug: ^1^1C-methionine
Sponsors: St. Jude Children's Research Hospital
Active, not recruiting -
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Posted: March 5th, 2013, 3:00pm GMT
Condition: Refractory and/or Relapsed Metastatic Solid Tumors
Interventions: Drug: Cyclophosphamide; Drug: Fludarabine; Radiation: low dose total body irradiation; Drug: Melphalan; Drug: Tacrolimus
Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Recruiting -
Auto Transplant for High Risk or Relapsed Solid or CNS Tumors
Posted: January 6th, 2012, 3:00pm GMT
Conditions: Ewing's Family Tumors; Renal Tumors; Hepatoblastoma; Rhabdomyosarcoma; Soft Tissue Sarcoma; Primary Malignant Brain Neoplasms; Retinoblastoma; Medulloblastoma; Supra-tentorial Primative Neuro-Ectodermal Tumor (PNET); Atypical Teratoid/Rhabdoid Tumor (AT/RT); CNS Tumors; Germ Cell Tumors
Interventions: Drug: Ifosfamide; Drug: Etoposide; Drug: Mesna; Biological: G-CSF; Drug: Busulfan; Drug: Melphalan; Drug: Thiotepa; Biological: Autologous stem cell infusion; Radiation: Radiation; Drug: Carboplatin; Drug: Paclitaxel; Procedure: Leukapheresis; Drug: Anti-seizure prophylaxis; Drug: Ursodiol
Sponsor: Masonic Cancer Center, University of Minnesota
Recruiting -
Molecular Analysis Of Solid Tumors
Posted: January 15th, 2010, 3:00pm GMT
Condition: Pediatric Solid Tumors
Intervention:
Sponsors: St. Jude Children's Research Hospital; Alex's Lemonade Stand Foundation
Recruiting -
Collecting and Storing Tissue, Blood, and Bone Marrow Samples From Patients With Rhabdomyosarcoma or Other Soft Tissue Sarcoma
Posted: June 12th, 2009, 2:00am GMT
Conditions: Adult Rhabdomyosarcoma; Childhood Desmoplastic Small Round Cell Tumor; Chordoma; Desmoid-Type Fibromatosis; Metastatic Childhood Soft Tissue Sarcoma; Non-Metastatic Childhood Soft Tissue Sarcoma; Previously Treated Childhood Rhabdomyosarcoma; Recurrent Adult Soft Tissue Sarcoma; Recurrent Childhood Rhabdomyosarcoma; Recurrent Childhood Soft Tissue Sarcoma; Rhabdomyosarcoma; Stage I Adult Soft Tissue Sarcoma AJCC v7; Stage II Adult Soft Tissue Sarcoma AJCC v7; Stage III Adult Soft Tissue Sarcoma AJCC v7; Stage IV Adult Soft Tissue Sarcoma AJCC v7; Untreated Childhood Rhabdomyosarcoma
Interventions: Other: Cytology Specimen Collection Procedure; Other: Laboratory Biomarker Analysis
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Completed -
Collecting and Storing Tissue From Young Patients With Cancer
Posted: May 12th, 2009, 2:00pm GMT
Conditions: Acute Lymphoblastic Leukemia; Acute Myeloid Leukemia; Central Nervous System Neoplasm; Ewing Sarcoma; Germ Cell Tumor; Leukemia; Lymphoma; Malignant Neoplasm; Neuroblastoma; Osteosarcoma; Retinoblastoma; Rhabdoid Tumor; Rhabdomyosarcoma; Soft Tissue Sarcoma
Interventions: Other: Cytology Specimen Collection Procedure; Other: Laboratory Biomarker Analysis
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting -
Methionine PET/CT Studies In Patients With Cancer
Posted: February 10th, 2009, 3:00pm GMT
Conditions: Brain Tumors and/or Solid Tumors Including; Brain Stem Glioma; High Grade CNS Tumors; Ependymoma; Medulloblastoma; Craniopharyngioma; Low Grade CNS Tumors; Hodgkin Lymphoma; Non Hodgkin Lymphoma; Ewing Sarcoma; Osteosarcoma; Rhabdomyosarcoma; Neuroblastoma; Other
Intervention: Drug: Methionine
Sponsor: St. Jude Children's Research Hospital
Recruiting -
Long-Term Follow-Up of Patients Who Have Participated in Children's Oncology Group Studies
Posted: August 18th, 2008, 2:00pm GMT
Conditions: Acute Lymphoblastic Leukemia; Brain Neoplasm; Hematopoietic Cell Transplantation Recipient; Hodgkin Lymphoma; Osteosarcoma; Rhabdomyosarcoma
Interventions: Procedure: Assessment of Therapy Complications; Other: Questionnaire Administration
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting -
Irinotecan and Carboplatin as Upfront Window Therapy in Treating Patients With Newly Diagnosed Intermediate-Risk or High-Risk Rhabdomyosarcoma
Posted: February 11th, 2004, 3:00am GMT
Conditions: Sarcoma
Interventions: Biological: filgrastim; Drug: carboplatin; Drug: cyclophosphamide; Drug: dexrazoxane hydrochloride; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: ifosfamide; Drug: irinotecan hydrochloride; Drug: vincristine sulfate; Procedure: conventional surgery; Radiation: radiation therapy
Sponsors: Memorial Sloan Kettering Cancer Center; National Cancer Institute (NCI)
Active, not recruiting